EXPERIMENTAL STUDY

The in vivo effects of beta-3-receptor agonist CGP-12177 on thyroxine deiodination in cold-exposed, sympathectomized rat brown fat

Dietmar Hofer 1, Marcela Raíces 4, Konrad Schauenstein 2, Sepp Porta 2, Wolfgang Korsatko 3, Karl Hagmüller 1 and Angel Zaninovich 4

Departments of 1Zoology, 2Pathophysiology and 3Pharmaceutical Chemistry, University of Graz, Austria and 4Hospital de Clínicas and Ingebi, University of Buenos Aires, Argentina

Correspondence should be addressed to A Zaninovich, Hospital de Clínicas, C.C. 29 Ofic. Facultad, 1453 Buenos Aires, Argentina; Email: azaninovich@sinectis.com.ar

Abstract

Objective: The effects of the beta-3-receptor agonist CGP-12177 on thyroxine (T4) deiodination in sympathectomized (SX) interscapular brown adipose tissue (BAT) were assessed in 300 g body weight (BW) Wistar rats.

Design: Seven days after SX, groups of rats were implanted s.c. with pellets containing 5 mg CGP-12177 or 5 mg norepinephrine (NE) and were immediately placed at 4°C for 24 h. Other SX groups were injected with CGP-12177 or NE 1 mg/kg BW i.p. and placed in the cold for 4 h. The latter group was injected, in addition, with prazosin 0.4 mg/100 g BW i.p. or propranolol 0.5 mg/100 g BW i.p. 15 min before and 2 h after the administration of CGP-12177 or NE.

Methods: Two hours after the last injection of prazosin or propranolol, animals were killed and BAT was removed, homogenized and centrifuged at 500 g for 10 min at 4°C. The infranatants were incubated during 60 min in the presence of dithiothreitol and 1 μCi [125I]T4. Aliquots were chromatographed on paper for the measurement of [125I]T4 and its deiodinated subproducts.

Results: CGP-12177 restored normal T4 deiodination in SX BAT from both groups, but NE was slightly more effective. Propranolol, although not prazosin, blocked the CGP-12177 effects. Contrariwise, the NE-induced rise in deiodination was blocked by prazosin and to a lesser extent by propranolol.

Conclusions: The results indicate that CGP-12177 stimulated the in vivo activation of 5'-deiodinase type II activity predominantly via beta-3-receptor, without participation of alpha-1-receptors.
Reagents

Double-labeled [3',5'-125I]T4 with a specific activity of 1280 µCi/µg was purchased from Amersham International plc. Amersham, Bucks, UK, and was used within a week of arrival. It was 95% pure and the rest was 125I and traces of [125I]T3. The proportions of these contaminants were determined in duplicate by chromatographic runs in each experiment and were subtracted from the results. 1,4-Dithio-s^-threitol (DTT), NE bitartrate, prazosin and DL-propranolol were purchased from Sigma Chemical Co., St Louis, MO, USA. The beta-3-receptor agonist CGP-12177 was kindly provided by Novartis, Basel, Switzerland.

Experiment 1

Groups of rats were subjected to BAT SX or sham operation in the manner described in a previous report (12). After closing the surgical incision, animals were returned to individual cages and maintained at ~24°C with food and water freely available for 7 days. On day 8, sham and SX rats were implanted, s.c., under light ether anesthesia, with pellets containing either 5 mg CGP-12177 or 5 mg NE. Another group of SX rats were implanted with pellets devoid of CGP-12177 or NE, thus serving as SX controls. The pellets were made up of a polysaccharide matrix (Eudragit, Röhm GmbH, Darmstadt, Germany) and the respective adrenergic compounds, and were prepared as described elsewhere (13). Immediately thereafter, rats were placed in individual cages in a cold-room at 4°C, with free access to food and tap water. After 24 h, animals were killed by cervical dislocation, blood and BAT were obtained and BAT was immediately processed as described below.

Experiment 2

Groups of SX rats were injected with a single dose of either CGP-12177 or NE 1 mg/kg BW. i.p. Sham-operated rats received the vehicle alone. Animals were immediately placed in individual cages in a cold-room at 4°C. Fifteen minutes before and 2 h after the injection of CGP-12177 or NE, rats received prazosin 0.4 mg or propranolol 0.5 mg/100 g BW, i.p. Rats were killed 2 h after the last injection of prazosin or propranolol. BAT was removed and processed. Five rats per group were studied.

Deiodination studies

BAT homogenates were prepared as described before (14). Tissue samples were homogenized in ice-cold buffer containing sucrose (320 mmol/l) and Hepes (10 mmol/l) in a proportion of 1 g BAT to 4 ml buffer, pH 7.4. The mixture was centrifuged at 500 g for 10 min at 4°C. The infranatant (6.8–9.7 mg protein/ml) contained the deiodinating activity and was used for the study of T4 deiodination. To 200 µl aliquots of infranatants were added 10 mmol/l DTT (final concentration) and 1 µCi [125I]T4 carrying 1 pmol T4. The final substrate concentration was 5.1 mmol/l. A previous study (14) showed that larger T4 concentrations (1 µmol/l) were needed to inhibit T4 deiodination under these experimental conditions. Tissue-free tubes containing reagents in concentrations similar to those added to the homogenates, plus labeled T4, were also prepared. All aliquots and blanks were incubated in a water-bath under continuous shaking at 37°C for 18 h. Chromatograms were cut into 0.5 cm segments and 125I in them counted. The resulting histograms allowed a clear identification of the radioactive compounds, which were correlated with the stained areas in duplicate strips. Radioactivity in the chromatograms was corrected for the proportion of each radioactive compound other than [125I]T4 present in the chromatographic runs of the standard solutions as received from the commercial source and of blanks incubated concomitantly with the homogenates. This chromatographic technique allowed a reliable assessment of the percentage distribution of the radioactive compounds generated during the incubation of labeled T4 (15, 16). The absolute amount of [125I]T4 deiodinated during the incubation period was derived from knowing the percentage of [125I]T4 present in the homogenates and the amount of added T4. The values were expressed in pg/mg of protein/h.

NE measurement

BAT NE was measured by techniques described elsewhere (17). Briefly, BAT was homogenized at 4°C in perchloric acid, EDTA and ascorbic acid and centrifuged for 10 min at 24,000 g. Supernatants were treated with ammonium chloride, EDTA and a diphenylborate–ethanolamine complex, and also with octanol–heptane and a tetraoctylamino–bromide complex. After 5 min stirring and 5 min centrifugation the supernatant was resuspended in octanol, extracted with acetic acid and injected into an HPLC apparatus for the analysis of catecholamines using Beckman System Gold software (Fullerton, CA, USA) and a BAS-LG-4B electrochemical detector (Biolab, Vienna, Austria). The limit of detection was 50 pg NE/ml. Results are expressed as pg/mg wet tissue.

Other methods

Statistical analyses were performed by ANOVA and Duncan’s test.
Results

Results of BAT weight, protein and NE concentrations after 24 h of cold exposure are shown in Table 1. BAT denervation induced a significant decrease in total proteins (P < 0.01 versus sham group), and this effect was unchanged by the injection of CGP-12177 or NE. Seven days after SX, BAT NE declined to the limits of detection (P < 0.01). The values increased markedly after the implantation of NE pellets but reached only one-half the concentration of NE seen in normal BAT. BAT concentration of CGP-12177 could not be determined. The distribution of deiodinated T4 among its metabolic subproducts in rats treated with receptor blockers is seen in Table 2. The results show that more than 97% of deiodinated T4 was apportioned almost equally between T3 and iodide, the rest being traces of T2. Comparable values in each column: a versus b: P < 0.01; a versus c: P < 0.05; b versus c: P < 0.01 (ANOVA).

Discussion

Activation of BAT thermogenesis involves the binding of NE to BAT beta-3-adrenergic receptors, followed by the stimulation of adenylate cyclase (5). Different subtypes of beta-receptors have tissue selectivity, e.g. beta-1 in heart, beta-2 in lung and beta-3 in adipose tissue. However, all three beta-receptors coexist in BAT (19, 20). It is also clear that BAT expresses the genes of the three beta-receptors and that each receptor mediates a normal T4 deiodination in SX rats. Although the study was terminated at 4 h, it is possible that the stimulatory action of CGP-12177 may have lasted longer, similar to the effects of NE seen in earlier studies (18). The effects of CGP-12177 were abolished by propranolol (P < 0.01) whereas prazosin failed to induce significant changes. Because BAT from SX rats was devoid of NE, the results indicate that propranolol had blocked predominantly or solely the action of CGP-12177. Conversely, prazosin was effective in blocking the stimulatory activity of NE (P < 0.01), as shown in earlier studies of Silva & Larsen (7, 18). However, propranolol also impaired the response to NE (P < 0.05), an effect not seen in those reports.

Table 1 BAT weight, protein and NE contents after a 24 h cold exposure. Means ± s.d. BAT NE was measured in separate groups of similarly treated rats. Numbers in parentheses indicate number of rats. Pellets containing 5 mg CGP-12177 or NE were implanted s.c. immediately before animals were placed in a cold-room.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Body weight (g)</th>
<th>BAT weight (mg)</th>
<th>BAT protein (mg/ml)</th>
<th>BAT NE (pg/mg tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham (8)</td>
<td>310 ± 28</td>
<td>288 ± 33&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.8 ± 1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>676 ± 85&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>SX (8)</td>
<td>328 ± 22</td>
<td>221 ± 43&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.6 ± 0.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>90 ± 27&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>CGP-12177 (7)</td>
<td>315 ± 28</td>
<td>238 ± 32</td>
<td>8.6 ± 1.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>—</td>
</tr>
<tr>
<td>NE (7)</td>
<td>296 ± 25</td>
<td>266 ± 32</td>
<td>8.6 ± 1.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>299 ± 31&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>P</sup> values in each column: <sup>a</sup> versus <sup>b</sup>: P < 0.01; <sup>a</sup> versus <sup>c</sup>: P < 0.05; <sup>b</sup> versus <sup>c</sup>: P < 0.01 (ANOVA).

Table 2 T4 deiodination and its subproducts as % of added [125I]T4 in rats studied 4 h after the injection of the adrenergic agonist. Means ± s.e. Sham and SX rats were injected with CGP-12177 or NE 1 mg/kg BW, i.p. and placed in a cold-room at 4°C. Prazosin and propranolol were injected 15 min before and 2 h after the administration of the respective adrenergic agonist. Animals were killed 2 h after the last injection of the receptor blocker. Five rats per group were studied.

<table>
<thead>
<tr>
<th>Groups</th>
<th>[125I]T4 deiodinated</th>
<th>[125I]T3 produced</th>
<th>[125I]T3 produced</th>
<th>Others*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>65.2 ± 7.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>32.8 ± 3.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>30.8 ± 2.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.3 ± 1.9</td>
</tr>
<tr>
<td>SX</td>
<td>23.0 ± 3.9&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10.6 ± 1.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>11.4 ± 2.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.4 ± 1.1</td>
</tr>
<tr>
<td>SX + CGP-12177</td>
<td>56.3 ± 5.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>25.9 ± 1.8&lt;sup&gt;c&lt;/sup&gt;</td>
<td>28.9 ± 4.3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>2.1 ± 1.8</td>
</tr>
<tr>
<td>Prazosin</td>
<td>47.5 ± 5.1&lt;sup&gt;d&lt;/sup&gt;</td>
<td>22.9 ± 2.4</td>
<td>23.5 ± 2.8</td>
<td>0.9 ± 0.7</td>
</tr>
<tr>
<td>Propranolol</td>
<td>25.6 ± 4.4&lt;sup&gt;e&lt;/sup&gt;</td>
<td>13.2 ± 2.3&lt;sup&gt;d&lt;/sup&gt;</td>
<td>10.8 ± 1.6&lt;sup&gt;d&lt;/sup&gt;</td>
<td>2.1 ± 1.4</td>
</tr>
<tr>
<td>SX + NE</td>
<td>64.1 ± 7.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>30.8 ± 3.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>32.3 ± 3.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.8 ± 1.2</td>
</tr>
<tr>
<td>Prazosin</td>
<td>28.8 ± 4.3&lt;sup&gt;f&lt;/sup&gt;</td>
<td>13.7 ± 2.5&lt;sup&gt;f&lt;/sup&gt;</td>
<td>12.9 ± 2.1&lt;sup&gt;f&lt;/sup&gt;</td>
<td>1.7 ± 1.2</td>
</tr>
<tr>
<td>Propranolol</td>
<td>43.1 ± 5.9&lt;sup&gt;g&lt;/sup&gt;</td>
<td>20.7 ± 2.5&lt;sup&gt;d&lt;/sup&gt;</td>
<td>21.1 ± 2.4&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.5 ± 1.3</td>
</tr>
</tbody>
</table>

<sup>*Traces of [125I]T3, 3'-T2 and other unidentified substances. P values: a versus b, c versus d and e versus f, < 0.01; g versus h, < 0.02 (ANOVA). www.eje.org
The particular stimulatory action of NE (21, 22). The stimulation of beta-1- and beta-2-adrenoreceptors activates adenylate cyclase but does not lead to a thermogenic response in rat BAT, as measured by oxygen consumption (8). On the other hand, stimulation of the beta-3-receptor activates thermogenesis, which led to the suggestion that this receptor was predominantly or solely the adrenergic receptor coupled to BAT thermogenesis (8).

Early studies performed in vivo by Silva & Larsen (7, 18) had shown that pretreatment of rats with the specific alpha-1-receptor antagonist prazosin inhibited NE- or cold-stimulated increases in BAT deiodinase. These findings led to the conclusion that BAT 5'-deiodinase activity was predominantly mediated via alpha-1-adrenoreceptors, with a minor participation of beta-receptors. Further studies by Raasmaja & Larsen (9) performed in cultured brown adipocytes showed a complex interrelationship between alpha-1- and beta-receptors, suggesting a synergistic action between these two types of receptors. The present findings indicate that the in vivo administration of CGP-12177 stimulated 5'-deiodination with a time-course comparable to that of NE. The pellets used in this study released the adrenergic compounds steadily during a period of approximately 72 h, with a peak between 24 and 48 h (23). When CGP-12177 was administered by a single i.p. injection, it restored deiodination to within normal values, although slightly lower than the effect of NE. The 4 h effects of CGP-12177 were abolished by propranolol but not by prazosin, thus confirming that beta-receptors were mostly or solely involved in the in vivo activation of 5'-DII. These results correlate with those obtained in isolated brown adipocytes in vitro by Pavelka et al. (24) and Hernandez & Obregón (25). In rats injected with NE, however, prazosin – and to a lesser extent propranolol – blocked the NE effect, thereby suggesting that the natural agonist activated 5'-DII in vivo via alpha-1-receptors and to a lesser extent through beta-receptors. A selective, high affinity beta-3-receptor blocker which would facilitate the analysis of the results has not yet been identified. We used propranolol, whose affinity for beta-3-receptors is far below (26) its affinity for beta-1 and beta-2-receptors (11, 21). Based on the sharp inhibition of CGP-12177 by propranolol and the fact that this adrenergic agonist interacts with receptors other than those with which NE interacts (27), one cannot rule out that beta-receptor subtypes other than beta-3 may have participated in the BAT response to CGP-12177. NE was slightly more efficient than the synthetic agonist in promoting 5'-DII activity. Other parameters of BAT thermogenesis, such as oxygen consumption (11) and GDP binding to BAT mitochondrial proteins (A Zaninovich) also showed that NE was moderately more effective. This could be the result of a complex mechanism for the in vivo activation of 5'-DII, which would involve NE and more than one type of adrenergic receptor. Zhao et al. (28) showed that both beta-3- and alpha-1-receptors mediated the activation of BAT oxygen consumption. The alpha-1-receptor appeared to potentiate the ability of cAMP to stimulate thermogenesis synergistically with the beta-3-receptor. A synergism between beta- and alpha-1-receptors in the stimulation of 5'-DII activity was observed in isolated adipocytes (9) although other in vitro studies (24, 25) failed to detect a role for alpha-1-receptors, perhaps due to different cell culture.
conditions. The present data indicate that the in vivo administration of CGP-12177 can activate BAT 5'-DIID via beta-receptors without a significant participation of alpha-1-receptors. It should be kept in mind, however, that this pathway may differ from that used by the natural agonist under physiological conditions.

Acknowledgements

This work was supported by grants 5326 from der Österreichischen Nationalbank, Vienna, Austria and PIP 4002/96 and PLCT/97 from the National Research Council of Argentina.

References


3 Silva JE. Full expression of uncoupling protein gene requires the concurrence of norepinephrine and triiodothyronine. Molecular Endocrinology 1988 2 706–713.


5 Nichols DG & Locke RM. Thermogenic mechanisms in brown fat. Physiological Reviews 1984 64 1–64.

6 Himms-Hagen J. Brown adipose tissue thermogenesis. false.


